The Future in Cannabis. WorldWide.

Tag: DNA

TheraCann Launches ETCH BIOTRACE™ Technology

Panama Pacifico, Panama, July 31st, 2018 – TheraCann International Benchmark Corporation (“TheraCann”), a leading full service international cannabis business and “seed to sale” technology firm in conjunction with Applied DNA Sciences, Inc., (NASDAQ: APDN), the leader in molecular technologies for supply chain transparency, announced the successful launch of their breakthrough ETCH biotrace™ technology. The  molecular “tag and trace” system will be included with TheraCann’s BenchmarkSOLUTION of licensing, project management, security, cultivation, and analysis services.

TheraCann’s ETCH biotrace™ platform is poised to further refine and transform the cannabis regulatory environment by adding capabilities that allow for the forensic tracking of cannabis and cannabis derivatives across the supply chain. Whether it is introduced at the cultivator, processor or manufacturer level, ETCH biotrace links a unique molecular tag to the cannabis plant that will survive conversion or extraction. Using a simple hand-held device, molecular testing can be performed at any point in the supply chain to verify compliance. The technology also has the potential to drive a sea change in the way brands catalog, manage and track their intellectual property.

The rapid global adoption of cannabis legislation has accelerated the need to secure and truly validate cannabis supply chains from seed-to- sale. Current systems, many of which rely on RFID or bar code technologies, are capable of accurately tacking cannabis supply chains through the cultivation stage but cannot forensically track cannabis and/or cannabis derivative products back to a specific source once the physical tags and packaging are removed.

“TheraCann is excited to fully introduce this  breakthrough molecular tag and trace technology. Global regulatory bodies and cannabis brands have been limited by their reliance on traditional RFID  and stickering systems,” said Jason Warnock, Chief Executive Officer of TheraCann International Benchmark Corporation. “The combination of TheraCann’s integration software and EPCIS Standardized blockchain systems through Multichain Ventures (dba the Tokes Platform), with Applied DNA Science’s proven CertainT® platform creates a safe and secure way to manage the legal supply chain.”

“The molecular tags used in the ETCH biotrace system are considered GRAS (Generally Recognized as Safe), they are non GMO,” said Dr. James Hayward, President and CEO of Applied DNA Sciences. “The typical daily diet includes about 100 parts DNA per million parts of food. Orally ingested DNA is hydrolyzed by the pH in the stomach. Our molecular tags are very small; too small to function as genes. Typical tagging levels of use are in parts per billion, levels too small to have any impact on form or function, or the biological properties of cannabis.”

The ETCH biotrace patented technology provides true traceability including the ability to track products from cultivation, extraction and derivative processing into edibles or other forms that will provide a clear method to eliminate black and grey market products from entering the regulated marketplace worldwide.

TheraCann’s ETCH biotrace technology is currently in beta testing with multiple cultivators but will be available to clients, regulatory bodies and cannabis brands in legal municipalities throughout the world.

More information about ETCH biotrace is available at www.etchbiotrace.com

About TheraCann International Benchmark Corporation
Founded in 2004, TheraCann International Benchmark Corporation offers a one-stop, full-service solution for the International cannabis marketplace. TheraCann provides business, technology and industry experts who apply advanced technology and help clients design, build and run their cannabis businesses. Integrating nearly 3.5 million square feet of cannabis operations  and the successful launch of groundbreaking Enterprise Resource Planning (ERP) software, Aeroponic cultivation systems and patented genetic tracking and diversion prevention systems, TheraCann provides cannabis-related businesses with solutions to fit their regulatory requirements.

 

More information about TheraCann is available at www.theracanncorp.com. Follow us on Twitter or Linkedin

 

About Applied DNA Sciences

Applied DNA is a provider of molecular technologies that enable supply chain security, anti-counterfeiting and anti-theft technology, product genotyping and DNA mass production for diagnostics and therapeutics.

Applied DNA makes life real and safe by providing innovative, molecular-based technology solutions and services that can help protect products, brands, entire supply chains, and intellectual property of companies, governments and consumers from theft, counterfeiting, fraud and diversion. The proprietary DNA-molecular based “CertainT®” platform can be used to identify, tag, test, and track products, to help assure authenticity, origin, traceability, sustainability and quality of products. SigNature® DNA describes the core technology ingredient that is at the heart of a family of uncopyable, security and authentication solutions such as SigNature® T and fiberTyping®, targeted toward textiles and apparel, BackTrac™ and DNAnet®, for anti-theft and loss prevention, and digitalDNA®, providing powerful track-and-trace. All provide a forensic chain of evidence and can be used to prosecute perpetrators. Applied DNA Sciences is also engaged in the large-scale production of specific DNA sequences using the polymerase chain reaction.

Visit adnas.com for more information. Follow us on Twitter and LinkedIn.

TheraCann International announces patent license agreement covering cannabis tracking and traceability

Panama City, Panama – February 15th, 2018 – TheraCann International Benchmark Corporation, a leading full service international cannabis business and technology firm (“TheraCann”) is pleased to announce they have obtained exclusive license to the patent covering the company’s cannabis tracking and product diversion pipeline. Included as part of TheraCann’s new tracking division, the patent includes claims covering the attachment, detection and traceability of cannabis and includes an ongoing collaboration agreement with Dr. Dan Weinthal, Ph.D. in Plant science from Tel Aviv University in association with the ARO Volcani center, Israel.

“This is an exciting time for this industry,” Dr. Weinthal says “the ability to partner with a leading technology firm like TheraCann allows this science to innovate faster to deliver new products and solutions to protect legal cannabis markets worldwide.”

The global legal cannabis economy is expected to reach $140 Billion within 10 years with many Countries expanding medical and recreational usage restrictions in 2018. Australia, Canada, the United States, Columbia and Uruguay have already seen dramatic growth in their cannabis sectors, however the prospect of illegal products entering the legal supply chain remains a serious concern in each case. A new report by Arcview Market Research asserts that even though legal North American cannabis sales rose to $6.9 Billion in 2016, 87% of all cannabis sales still come from black or grey market sources.

Chris Bolton, Chief Operating Officer of TheraCann International, says “The future of the cannabis marketplace is in transforming the black-market system to legal and regulated sources. True traceability including the ability to track products from cultivation, extraction and derivative processing in to edibles or other forms, will provide a clear method to eliminate black market products from entering the regulated marketplace.”

This latest patent agreement fits with TheraCann’s recent joint venture announcement with TKS Ventures (dba Tokes Platform) and multi-year agreement with Applied DNA Sciences Inc (NASDAQ: APDN) to provide an immutable link between the authenticity of goods and the authenticity of digital transactions to create a unique and forensic identifier throughout the cannabis supply chain.

“Beyond the obvious cost savings in enforcement and diversion control,” says Bolton, “The consumer should be protected from harmful or even dangerous products entering the market, the retailer should be protected in the event of recall or product deficiencies, and the government or regulatory body should have the confidence to know, with certainty, that a product produced from a licensed facility is the same product that is ultimately sold to consumers.”

###

About TheraCann International Benchmark Corporation
Founded in 2004, TheraCann International Benchmark Corporation offers a one-stop, full-service solution for the International cannabis marketplace. TheraCann provides business, technology and industry experts who apply advanced technology and help clients design, build and run their cannabis businesses. With nearly 3.5 million square feet of cannabis operations under management and the successful launch of groundbreaking Enterprise Resource Planning (ERP) software, Aeroponic cultivation systems and patented genetic tracking and diversion prevention systems, TheraCann provides cannabis-related businesses with solutions to fit their regulatory requirements. More information about TheraCann is available at www.theracanncorp.com.

Press Contacts:
Jason Warnock
Managing Director, TheraCann Capital, TheraCann International
Email: jwarnock@theracanncorp.com

Applied DNA Sciences together with TheraCann International Will Create the First Seed-to-Sale Cannabis Tracking System Combining Molecular Tagging and Blockchain Technologies

STONY BROOK N.Y. (January 25th, 2018)Applied DNA Sciences, Inc. (NASDAQ: APDN, “Applied DNA,” “the Company”) today announced the signing of an initial two-year, $1 million contract with TheraCann International Benchmark Corporation, (“TheraCann”), a leading full service cannabis consultancy with operations in the US, Canada, Australia, Europe and South America, for the integration of the Company’s SigNature® molecular tagging and testing technology into TheraCann’s blockchain-based, seed-to-sale Enterprise Resource Platform (ERP) for legal cannabis operations. Under the terms of the contract, the companies have entered into a development and marketing agreement whereby Applied DNA will develop the technologies necessary to tag and authenticate legal cannabis throughout the supply chain and seamlessly integrate tagging and authentication data into TheraCann’s ERP and Blockchain platform. Applied DNA will receive an initial payment under its contract with TheraCann in the current quarter.

 

The rapid global adoption of legal cannabis legislation has accelerated the need to secure and truly validate cannabis supply chains from seed-to-sale. Current systems, many of which rely on RFID or bar code technologies, are capable of accurately tacking cannabis supply chains through the cultivation stage, but cannot forensically track cannabis and/or cannabis derivative products back to a specific source once the physical tags and packaging are removed. This gap allows the opportunity for illegal diversion and the introduction of illegally-sourced cannabis into legal supply chains. Combining molecular tagging with digital tracking enhances existing seed to sale systems to a new level of capability and compliance with state, and international laws and guidelines.

 

In response to the known limitations of current seed-to-sale systems, the State of Colorado this month introduced a new bill (SB 18-029) that mandates the addition of physical-chemical identifiers (PCIDs), of which Applied DNA’s molecular tags comply, to all legal cannabis plants grown in the state for the purposes of tracking cannabis and cannabis derivative products back to their origin. As the industry matures, next generation platforms, such as the one under development by Applied DNA and TheraCann, will support collaboration between regulators, law enforcement and producers in shaping the future of the cannabis industry.

 

“Our molecular tag creates an immutable link between the authenticity of goods and the authenticity of digital transactions to serve as a unique and forensic identifier that becomes part of a blockchain transaction throughout the supply chain,” stated Dr. James A. Hayward, president and chief executive officer of Applied DNA. “We believe that all blockchain platforms require forensic origination to ensure the veracity of the subsequent distributed ledger. The legal global cannabis industry is a complex supply chain and, therefore, a natural fit for our proven technologies across all medical and consumer applications. We are excited to work with TheraCann to enhance traceability in the expanding legal cannabis market.”

 

According to a market report from Arcview Research, the North American legal cannabis market in 2017 was valued at $6.7 billion per year and is expected to grow to $20.1 billion per year by 2021. While cannabis remains illegal under US federal law, eight states plus Washington DC have legalized cannabis for recreational use, while twenty-nine states plus Washington DC have legalized cannabis for medical use. An additional seven states are expected to legalize cannabis in the coming year[1]. 15 countries outside the USA have permitted medical cannabis.  Canada has been operating a federal medical cannabis program since 2001 and is expected to federally legalize recreational cannabis by mid-2018[2].

 

Chris Bolton, Chief Operating Officer for TheraCann added, “The platform under development by TheraCann and Applied DNA will be uniquely suited to meet the growing demand for true forensic level seed-to-sale tracking and diversion control systems globally. As each new state or country legalizes medicinal or recreational cannabis, it creates an opportunity for the broad-scale adoption of our technologies.”

 

About Applied DNA Sciences

Applied DNA is a provider of molecular technologies that enable supply chain security, anti-counterfeiting and anti-theft technology, product genotyping and DNA mass production for diagnostics and therapeutics. The Company makes life real and safe by providing innovative, molecular-based technology solutions and services that can help protect products, brands, entire supply chains, and intellectual property of companies, governments and consumers from theft, counterfeiting, fraud and diversion.

The proprietary DNA-based CertainT® platform can be used to identify, tag, test, and track products, to help assure authenticity, origin, traceability, sustainability and quality of products. SigNature® DNA describes the core technology ingredient that is at the heart of a family of uncopyable, security and authentication solutions such as SigNature®T and fiberTyping®, targeted towards textiles and apparel, BackTrac® and DNAnet®, for anti-theft and loss prevention, and digitalDNA®, providing powerful track-and-trace. All provide a forensic chain of evidence, and can be used to prosecute perpetrators. Applied DNA Sciences is also engaged in the large-scale production of specific DNA sequences using the polymerase chain reaction.

Visit adnas.com for more information. Follow us on Twitter and LinkedIn. Join our mailing list.

 

About TheraCann International Benchmark Corporation

Founded in 2004, TheraCann International Benchmark Corporation offers a one-stop, full-service solution for the International cannabis marketplace including, government applications, planning, facility design, cultivation, marketing and communications. With nearly 5 million square feet of cannabis operations under management and the successful launch of groundbreaking Enterprise Resource Planning (ERP) software, Aeroponic cultivation systems and integrated finCEN compliant blockchain solutions, TheraCann provides cannabis-related businesses with solutions to fit their regulatory requirements.

 

More information about TheraCann is available at www.theracanncorp.com. Follow TheraCann on Twitter and Linkedin.

[1] https://www.forbes.com/sites/tomangell/2017/12/26/these-states-are-likely-to-legalize-marijuana-in-2018/2/#73b90f161b04

[2] https://globalnews.ca/news/3867467/marijuana-legalization-canada-progress/